Clinical trial design for new cancer therapies has historically been focused on the tissue of origin of a tumor, but a paper from researchers at Memorial Sloan-Kettering Cancer Center published on September 26 in Nature Genetics ...
Sep 27, 2013
0
0
(AP) -- The Food and Drug Administration says Merck's cholesterol drug Vytorin helps reduce heart attack, stroke and related problems in patients with kidney disease, a potential new use for the blockbuster drug.
Oct 31, 2011
0
0
According to new research published Online First in the Lancet, body mass index may influence which blood pressure medications work best at reducing the major complications of high blood pressure (strokes, heart attacks, ...
Dec 5, 2012
0
0
Researchers have identified acute myeloid leukemia as a heterogeneous malignancy with the most common genomic alterations in NPM1, DNMT3A and FLT3. Midostaurin was the first FLT3 inhibitor FDA approved for AML and is standard ...
Oct 14, 2020
0
9
Identification of a non-traditional pathway for spiriting a cancer-promoting protein into the cell nucleus points to a possible combination therapy for esophageal cancer and indicates a mechanism of resistance for new drugs ...
Mar 19, 2012
0
0
A collaboration between scientists in Munich, Germany and Bloomington, USA may have overcome one of the major challenges drug makers have struggled with for years: Delivering powerful nuclear hormones to specific tissues, ...
Nov 13, 2012
0
1
Promising new data on drug combinations to treat metastatic melanoma are presented at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna.
Sep 29, 2012
0
0
Patients with chronic hepatitis C have a new option for treating the liver-damaging virus, with the approval of a combination treatment developed by AbbVie.
Dec 19, 2014
0
0
A University of Minnesota research team featuring researchers from the Institute for Molecular Virology, School of Dentistry and Center for Drug Design has developed a new delivery system for a combination of two FDA approved ...
Aug 30, 2013
0
0
Scientists have identified a drug combination, when used in advanced lung cancer patients, shows a survival advantage in patients who no longer respond to existing therapies. They found that bexarotene and erlotinib can each ...
Jun 2, 2011
0
0
